Skip to main content

Zika

1
Pipeline Programs
3
Companies
4
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

3 companies ranked by most advanced pipeline stage

Valneva
ValnevaAustria - Vienna
1 program
1
VLA1601Phase 11 trial
Active Trials
NCT06334393Completed150Est. Feb 2026
Allergy Therapeutics
Allergy TherapeuticsUK - West Sussex
3 programs
International Cohort Study of Children Born to Women Infected With Zika Virus During PregnancyN/A1 trial
One vector feedingN/A1 trial
Screening for LID Clinical Studies Unit Healthy Volunteer ProtocolsN/A1 trial
Active Trials
NCT04118738Completed272Est. Apr 2022
NCT03641339Completed95Est. May 2020
NCT01386424Recruiting5,000
Human BioSciences
Human BioSciencesWV - Martinsburg
1 program
International Cohort Study of Children Born to Women Infected With Zika Virus During PregnancyN/A

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
ValnevaVLA1601
Allergy TherapeuticsInternational Cohort Study of Children Born to Women Infected With Zika Virus During Pregnancy
Allergy TherapeuticsOne vector feeding
Allergy TherapeuticsScreening for LID Clinical Studies Unit Healthy Volunteer Protocols

Clinical Trials (4)

Total enrollment: 5,517 patients across 4 trials

NCT06334393ValnevaVLA1601

Phase 1 Trial to Assess the Safety and Immunogenicity of an Inactivated, Adjuvanted Whole Zika Virus Vaccine Candidate (VLA1601) in Healthy Adults

Start: Mar 2024Est. completion: Feb 2026150 patients
Phase 1Completed
NCT04118738Allergy TherapeuticsInternational Cohort Study of Children Born to Women Infected With Zika Virus During Pregnancy

International Cohort Study of Children Born to Women Infected With Zika Virus During Pregnancy

Start: Jun 2019Est. completion: Apr 2022272 patients
N/ACompleted
NCT03641339Allergy TherapeuticsOne vector feeding

Defining Skin Immunity of a Bite of Key Insect Vectors in Humans

Start: Sep 2018Est. completion: May 202095 patients
N/ACompleted
NCT01386424Allergy TherapeuticsScreening for LID Clinical Studies Unit Healthy Volunteer Protocols

Screening for LID Clinical Studies Unit Healthy Volunteer Protocols

Start: Jul 20115,000 patients
N/ARecruiting

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 actively recruiting trials targeting 5,517 patients
3 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.